ARCHIVES

Drug Development Effort Criticized

This article is from The Cancer Letter archive.

Vol. 01 No. 16 | April 18, 1975

Download PDF Visit The Full Archive

Related Articles

FDA Approves Folotyn For Peripheral T-Cell Lymphoma

September 25, 2009

NCI Sets Initial R01 Payline At 18th Percentile Under CR.

November 24, 2000

Judge Rules First Amendment Protects Distribution Of Off-Label Use Information

August 14, 1998

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012

FDA Accepts DCT Board’s Criteria For Approval Of New Drugs, Explains Plan for Early Action

February 17, 1989

Roswell Park, Karmanos Read The Cancer Letter Interactive.

December 1, 2000